Greenwich Lifesciences Inc (GLSI) FinancialsGLSIGreenwich Lifesciences Inc

Evaluating the bottom line, Greenwich Lifesciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -986.32%, provide a clear picture of how effectively GLSI converts its operational activities into shareholder value.

In the context of the broader market, GLSI competes directly with industry leaders such as RNA and VYGR. With a market capitalization of $230.01M, it holds a leading position in the sector. When comparing efficiency, GLSI's gross margin of N/A stands against RNA's 100.00% and VYGR's 100.00%. Such benchmarking helps identify whether Greenwich Lifesciences Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with the latest quarter showing a net loss of $3,948,675. The forward P/E ratio is currently at 0, indicating no earnings forecasted for the near term, which raises concerns about profitability.